82 related articles for article (PubMed ID: 29596904)
1. A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type.
Beylot-Barry M; Mermin D; Maillard A; Bouabdallah R; Bonnet N; Duval-Modeste AB; Mortier L; Ingen-Housz-Oro S; Ram-Wolff C; Barete S; Dalle S; Maubec E; Quereux G; Templier I; Bagot M; Grange F; Joly P; Vergier B; Vially PJ; Gros A; Pham-Ledard A; Frison E; Merlio JP
J Invest Dermatol; 2018 Sep; 138(9):1982-1989. PubMed ID: 29596904
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
Ghesquieres H; Chevrier M; Laadhari M; Chinot O; Choquet S; Moluçon-Chabrot C; Beauchesne P; Gressin R; Morschhauser F; Schmitt A; Gyan E; Hoang-Xuan K; Nicolas-Virelizier E; Cassoux N; Touitou V; Le Garff-Tavernier M; Savignoni A; Turbiez I; Soumelis V; Houillier C; Soussain C
Ann Oncol; 2019 Apr; 30(4):621-628. PubMed ID: 30698644
[TBL] [Abstract][Full Text] [Related]
3. Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-Cell Lymphoma, Leg-Type: A Case Report.
Zoli S; Pellegrini C; Casadei B; Broccoli A; Argnani L; Nanni L; Stefoni V; Zinzani PL
Chemotherapy; 2024; 69(1):23-26. PubMed ID: 37913761
[TBL] [Abstract][Full Text] [Related]
4. Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial.
Park C; Lee HS; Kang KW; Lee WS; Do YR; Kwak JY; Shin HJ; Kim SY; Yi JH; Lim SN; Lee JO; Yang DH; Jang H; Choi B; Lim J; Sun CH; Byun JM; Yoon SS; Koh Y
Nat Commun; 2024 Mar; 15(1):2776. PubMed ID: 38555311
[TBL] [Abstract][Full Text] [Related]
5. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Duell J; Abrisqueta P; Andre M; Gaidano G; Gonzales-Barca E; Jurczak W; Kalakonda N; Liberati AM; Maddocks KJ; Menne T; Nagy Z; Tournilhac O; Kuffer C; Bakuli A; Amin A; Gurbanov K; Salles G
Haematologica; 2024 Feb; 109(2):553-566. PubMed ID: 37646664
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Liquid Biopsy in Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type.
Guicheney M; Ducharme O; Caumont C; Gerard E; Dousset L; Beylot-Barry M; Merlio JP; Gros A; Pham-Ledard A
J Invest Dermatol; 2023 Jul; 143(7):1326-1329.e5. PubMed ID: 36693617
[No Abstract] [Full Text] [Related]
7. [Clinical characteristics and efficacy analysis of 11 patients with primary cutaneous diffuse large B-cell lymphoma, leg type].
Yuan YX; Shi Q; He Y; Qiu HL; Yi HM; Dong L; Wang L; Cheng S; Xu PP; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):690-693. PubMed ID: 37803847
[No Abstract] [Full Text] [Related]
8. [A case with giant ulcer caused by skin diffuse large B-cell lymphoma in the axilla].
Liu F; Zhang W; Xie WG; Chen L; Li Z
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Aug; 39(8):787-789. PubMed ID: 37805791
[TBL] [Abstract][Full Text] [Related]
9. Orbital Involvement by Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type.
de Guimarães JA; Chahud F; Wichert-Ana L; Cruz AAVE
Ophthalmic Plast Reconstr Surg; 2024 Mar-Apr 01; 40(2):e71. PubMed ID: 37450635
[No Abstract] [Full Text] [Related]
10. Primary cutaneous diffuse large B-cell lymphoma, leg type, presenting as subcutaneous nodules: Case series and comparison of treatment outcomes.
Besch JG; Kechter J; Hwang A; Shahin A; Bhullar P; Puri P; Butterfield R; Costello C; Rule W; Rosenthal A; DiCaudo DJ; Pittelkow M; Mangold A
JAAD Case Rep; 2023 Nov; 41():81-84. PubMed ID: 37916039
[No Abstract] [Full Text] [Related]
11. Tribulations of trials in aggressive lymphoma.
Barraclough A; Hawkes EA
Blood; 2023 Dec; 142(26):2232-2234. PubMed ID: 38153771
[No Abstract] [Full Text] [Related]
12. New perspectives for patients with primary cutaneous diffuse large B-cell lymphoma, leg-type.
Cencini E; Fabbri A; Cinotti E; Rubegni P; Bocchia M
Chemotherapy; 2023 Dec; ():. PubMed ID: 38071958
[No Abstract] [Full Text] [Related]
13. Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era.
Beygi S; Sadashiv S; Reilly JB; Khan C; Lister J
Leuk Lymphoma; 2018 Dec; 59(12):2847-2861. PubMed ID: 29616868
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review.
Zhang Y; Wang X; Liu Y; Sun C; Shi W; Huang H
Cancer Biol Ther; 2018 Jul; 19(7):549-553. PubMed ID: 29611764
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
Ujjani C; Wang H; Skarbnik A; Trivedi N; Ramzi P; Khan N; Cheson BD
Blood Adv; 2018 Apr; 2(7):762-768. PubMed ID: 29610115
[TBL] [Abstract][Full Text] [Related]
16. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study.
Dimopoulos M; Wang M; Maisnar V; Minarik J; Bensinger W; Mateos MV; Obreja M; Blaedel J; Moreau P
J Hematol Oncol; 2018 Apr; 11(1):49. PubMed ID: 29615082
[TBL] [Abstract][Full Text] [Related]
17. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
[TBL] [Abstract][Full Text] [Related]
18. Magarotto V, Bringhen S, Offidani M, et al. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.
Blood; 2018 Mar; 131(13):1495. PubMed ID: 29599148
[No Abstract] [Full Text] [Related]
19. Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review.
Iacoboni G; Zucca E; Ghielmini M; Stathis A
Ann Oncol; 2018 May; 29(5):1120-1129. PubMed ID: 29659676
[TBL] [Abstract][Full Text] [Related]
20. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Schmitz R; Wright GW; Huang DW; Johnson CA; Phelan JD; Wang JQ; Roulland S; Kasbekar M; Young RM; Shaffer AL; Hodson DJ; Xiao W; Yu X; Yang Y; Zhao H; Xu W; Liu X; Zhou B; Du W; Chan WC; Jaffe ES; Gascoyne RD; Connors JM; Campo E; Lopez-Guillermo A; Rosenwald A; Ott G; Delabie J; Rimsza LM; Tay Kuang Wei K; Zelenetz AD; Leonard JP; Bartlett NL; Tran B; Shetty J; Zhao Y; Soppet DR; Pittaluga S; Wilson WH; Staudt LM
N Engl J Med; 2018 Apr; 378(15):1396-1407. PubMed ID: 29641966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
